Literature DB >> 25979851

Targeting mechanisms at sites of complement activation for imaging and therapy.

V Michael Holers1.   

Abstract

The complement system plays a key role in many acute injury states as well as chronic autoimmune and inflammatory diseases. Localized complement activation and alternative pathway-mediated amplification on diverse target surfaces promote local recruitment of pro-inflammatory cells and elaboration of other mediators. Despite a general understanding of the architecture of the system, though, many of the mechanisms that underlie site-specific complement activation and amplification in vivo are incompletely understood. In addition, there is no capability yet to measure the level of local tissue site-specific complement activation in patients without performing biopsies to detect products using immunohistochemical techniques. Herein is reviewed emerging evidence obtained through clinical research studies of human rheumatoid arthritis along with translational studies of its disease models which demonstrate that several parallel mechanisms are involved in site-specific amplification of activation of the complement system in vivo. Among these processes are de-regulation of the alternative pathway, effector pathway-catalyzed amplification of proximal complement activation, recognition of injury-associated ligands by components of the lectin pathway, and engagement of pathogenic natural antibodies that recognize a limited set of injury-associated neoepitopes. Studies suggest that each of these inter-related processes can play key roles in amplification of complement-dependent injury on self-tissues in vivo. These findings, in addition to development of an imaging strategy described herein designed to quantitatively measure local complement C3 fixation, have relevance to therapeutic and diagnostic strategies targeting the complement system.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Alternative pathway; Arthritis; Complement therapeutics; Effector pathways; Lectin pathway; Molecular imaging; Pathogenesis

Mesh:

Substances:

Year:  2015        PMID: 25979851      PMCID: PMC4627863          DOI: 10.1016/j.imbio.2015.04.005

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  79 in total

1.  A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis.

Authors:  A C Bakker; F A Van de Loo; L A Joosten; M B Bennink; O J Arntz; I P Dmitriev; E A Kashentsera; D T Curiel; W B van den Berg
Journal:  Gene Ther       Date:  2001-12       Impact factor: 5.250

2.  A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration.

Authors:  Anne E Hughes; Nick Orr; Hossein Esfandiary; Martha Diaz-Torres; Timothy Goodship; Usha Chakravarthy
Journal:  Nat Genet       Date:  2006-09-24       Impact factor: 38.330

Review 3.  Atypical haemolytic uraemic syndrome.

Authors:  David Kavanagh; Timothy H J Goodship; Anna Richards
Journal:  Br Med Bull       Date:  2006-09-11       Impact factor: 4.291

4.  Local production of complement proteins in rheumatoid arthritis synovium.

Authors:  Elena Neumann; Scott R Barnum; Ingo H Tarner; Josh Echols; Martin Fleck; Martin Judex; Frank Kullmann; John D Mountz; Jürgen Schölmerich; Steffen Gay; Ulf Müller-Ladner
Journal:  Arthritis Rheum       Date:  2002-04

5.  Particularities of the vasculature can promote the organ specificity of autoimmune attack.

Authors:  Bryce A Binstadt; Pratik R Patel; Herlen Alencar; Peter A Nigrovic; David M Lee; Umar Mahmood; Ralph Weissleder; Diane Mathis; Christophe Benoist
Journal:  Nat Immunol       Date:  2006-01-29       Impact factor: 25.606

Review 6.  Mannan-binding lectin--a soluble pattern recognition molecule.

Authors:  Mihaela Gadjeva; Kazue Takahashi; Steffen Thiel
Journal:  Mol Immunol       Date:  2004-06       Impact factor: 4.407

7.  C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.

Authors:  Agustín Tortajada; Hugo Yébenes; Cynthia Abarrategui-Garrido; Jaouad Anter; Jesús M García-Fernández; Rubén Martínez-Barricarte; María Alba-Domínguez; Talat H Malik; Rafael Bedoya; Rocío Cabrera Pérez; Margarita López Trascasa; Matthew C Pickering; Claire L Harris; Pilar Sánchez-Corral; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

8.  Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation.

Authors:  Hui-fang Zhou; Huimin Yan; Paula Bertram; Ying Hu; Luke E Springer; Robert W Thompson; John A Curci; Dennis E Hourcade; Christine T N Pham
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

9.  Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation.

Authors:  Stefan Heinen; Andrea Hartmann; Nadine Lauer; Ulrike Wiehl; Hans-Martin Dahse; Sylvia Schirmer; Katharina Gropp; Tina Enghardt; Reinhard Wallich; Steffi Hälbich; Michael Mihlan; Ursula Schlötzer-Schrehardt; Peter F Zipfel; Christine Skerka
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113

10.  Structural basis for engagement by complement factor H of C3b on a self surface.

Authors:  Hugh P Morgan; Christoph Q Schmidt; Mara Guariento; Bärbel S Blaum; Dominic Gillespie; Andrew P Herbert; David Kavanagh; Haydyn D T Mertens; Dmitri I Svergun; Conny M Johansson; Dušan Uhrín; Paul N Barlow; Jonathan P Hannan
Journal:  Nat Struct Mol Biol       Date:  2011-02-13       Impact factor: 15.369

View more
  4 in total

Review 1.  New milestones ahead in complement-targeted therapy.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Semin Immunol       Date:  2016-06-16       Impact factor: 11.130

Review 2.  The complement system as a potential therapeutic target in rheumatic disease.

Authors:  Leendert A Trouw; Matthew C Pickering; Anna M Blom
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

3.  Complement-containing small extracellular vesicles from adventitial fibroblasts induce proinflammatory and metabolic reprogramming in macrophages.

Authors:  Sushil Kumar; Maria G Frid; Hui Zhang; Min Li; Suzette Riddle; R Dale Brown; Subhash Chandra Yadav; Micaela K Roy; Monika E Dzieciatkowska; Angelo D'Alessandro; Kirk C Hansen; Kurt R Stenmark
Journal:  JCI Insight       Date:  2021-11-08

4.  Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension.

Authors:  Maria G Frid; B Alexandre McKeon; Joshua M Thurman; Bradley A Maron; Min Li; Hui Zhang; Sushil Kumar; Timothy Sullivan; Jennifer Laskowsky; Mehdi A Fini; Samantha Hu; Rubin M Tuder; Aneta Gandjeva; Martin R Wilkins; Christopher J Rhodes; Pavandeep Ghataorhe; Jane A Leopold; Rui-Sheng Wang; V Michael Holers; Kurt R Stenmark
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.